How KPV Works: Mechanism and Pharmacology
How KPV works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.
- Class
- Anti-inflammatory tripeptide
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
- Routes studied
- in drinking water (mice); systemic; central and peripheral
- Half-life
- [pending]
- by route, with source
How long it acts
No published half-life found for KPV (PubMed search, 11 Oct 2026)
Full detail, including drug-testing windows, is on the KPV half-life page.
The signalling pathways named in the studies
In intestinal and immune cells, nanomolar KPV inhibited NF-kappaB and MAP kinase signalling and cut pro-inflammatory cytokine secretion (cell study).[6]
The same group found KPV acts via PepT1, a di/tripeptide transporter, in immune and intestinal epithelial cells (cell study).[6]
In human airway cells, KPV was associated with nuclear import, IκBα stabilisation and suppressed nuclear translocation of p65RelA (cell study).[7]
A mouse peritonitis study concluded KPV is unlikely to act through melanocortin receptors and more likely acts by inhibiting IL-1beta functions (animal and cell study).[8]
What happens in cells and animals
In human keratinocytes KPV blocked reactive oxygen species production tied to ERK and p38 activation (cell study).[9]
In human keratinocyte cell lines, no rise in cyclic AMP was detected after alpha-MSH, KPV or ACTH peptides, though calcium signals appeared (cell study).[10]
A rabbit study found the 11-13 sequence part of alpha-MSH's fever-lowering message, with lower potency than the parent molecule (animal study).[11]
Delivery and stability, which limit how it can be studied
Through dermatomed human skin in the lab, KPV permeation by simple passive diffusion was below the detection limit.[12]
Under acid, alkali and hydrogen peroxide stress, KPV degraded mainly to lys-pro-diketopiperazine.[13]
What is not known in people
None of the 7 cached mechanism abstracts is a study in living human participants, so the pathways above are laboratory and animal findings.
Calculated from mechanism abstracts 7; human participant studies 0. Formula: count of cached mechanism abstracts reporting living human participants = 0
A dated PubMed search (2026-10-02) for KPV with half-life or pharmacokinetic terms returned 2 records, so no human dosing interval is established in the cached sources.
Calculated from evidence file web/src/data/evidence/kpv.json; query (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]); date 2026-10-02; count 2. Formula: count of PubMed records returned by the dated query
Related peptides
Common questions
How long does KPV act in the body?
We found no published half-life for KPV (PubMed search, 11 Oct 2026), so how long it acts is unknown.
How does KPV work?
In cell work the answer is a transporter and an inflammatory switch: KPV acts via PepT1 and inhibits NF-kappaB and MAP kinase signalling.[6]
More on KPV
Sources
- 1PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 6PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008PMID 18061177Accessed 2 Oct 2026
- 7Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.International journal of physiology, pathophysiology and pharmacology · 2012PMID 22837805Accessed 2 Oct 2026
- 8Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.The Journal of pharmacology and experimental therapeutics · 2003PMID 12750433Accessed 2 Oct 2026
- 9Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.Tissue & cell · 2025PMID 40073467Accessed 2 Oct 2026
- 10alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.The Journal of investigative dermatology · 2004PMID 15102092Accessed 2 Oct 2026
- 11Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit.Peptides · 1984PMID 6333677Accessed 2 Oct 2026
- 12Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.Journal of pharmaceutical sciences · 2017PMID 28343991Accessed 2 Oct 2026
- 13Stability-indicating HPLC assay for lysine-proline-valine (KPV) in aqueous solutions and skin homogenates.Biomedical chromatography : BMC · 2015PMID 25298219Accessed 2 Oct 2026
Found an error? Report a correction.